Impact of ITH on PRAD patients and feasibility analysis of the positive correlation gene MYLK2 applied to PRAD treatment.

Journal: Frontiers in genetics
Published Date: May 20, 2025

Abstract

INTRODUCTION: Prostate adenocarcinoma (PRAD) is an extremely widespread site of urological malignancy and is the second most common male cancer in the world. Currently, research progress in immunotherapy for prostate treatment is slower compared to other tumours, which is mainly considered to be caused by the low rate of immune response in prostate cancer as a cold tumour. Recent studies have shown that intra-tumour heterogeneity (ITH) is an important impediment to PRAD immunotherapy. Therefore, we set out to investigate the feasibility of judging patients' disease and knowing the clinical treatment based on the level of ITH.

Authors

  • Chuanyu Ma
    Department of Andrology and Sexual Medicine, The Second Hospital of Dalian Medical University, Dalian, China.
  • Guandu Li
    Department of Urology, First Affiliated Hospital of Dalian Medical University, Dalian, China.
  • Xiaohan Song
    Department of Hepatobiliary Surgery, Dalian Friendship Hospital, Dalian, China.
  • Xiaochen Qi
    Department of Urology, First Affiliated Hospital of Dalian Medical University, Dalian, China.
  • Tao Jiang
    Department of Respiratory and Critical Care Medicine, Center for Respiratory Medicine, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, China.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals